← Leaderboards
Donald W. Kufe
Dana-Farber Cancer Inst
$50,160,456
Attributed
$71,827,566
Total exposure
25
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$71,827,566 · 25
By mechanism
R01$24,241,204 · 7
UM1$23,631,028 · 1
U01$14,368,914 · 2
P50$4,021,672 · 3
P01$2,471,676 · 2
R21$2,347,044 · 6
Top collaborators
- Kwok Kin Wong21 shared
- Keith T Flaherty13 shared
- Geoffrey I Shapiro13 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Steven Dubois$3,581,513
- Geoffrey I Shapiro$18,639,470
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResponseSignal TransductionInhibitor/AntagonistTumorBasePathway InteractionsCellsGrantMucinsClinical TrialsOncogenicMucin 1 ProteinPharmacodynamicsSignal PathwayResistanceFundingApoptosisCancer CellC-TerminalN-TerminalTargeted AgentProgramsCancer Patient
Grant awards (151)
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2,074,014
UM1 · FY2025 · CA
Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer$673,898
R01 · FY2025 · CA
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$462,269
R01 · FY2025 · CA · contact PI
DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN$194,240
UM1 · FY2025 · CA
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$1,970,313
UM1 · FY2024 · CA
Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer$734,981
R01 · FY2024 · CA
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$466,587
R01 · FY2024 · CA · contact PI
MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer$450,429
R21 · FY2024 · CA · contact PI
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2,555,380
UM1 · FY2023 · CA
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression$204,707
R21 · FY2023 · CA · contact PI
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2022 · CA · contact PI
Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer$442,214
R21 · FY2022 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$388,836
R01 · FY2022 · CA · contact PI
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression$232,259
R21 · FY2022 · CA · contact PI
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2021 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$618,912
R01 · FY2021 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$396,771
R01 · FY2021 · CA · contact PI
XPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AML$124,999
UM1 · FY2021 · CA
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center$100,000
UM1 · FY2021 · CA
DanaâFarber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$6,942,412
UM1 · FY2020 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2020 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$624,332
R01 · FY2020 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$396,771
R01 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$2,325,303
UM1 · FY2019 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2019 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$611,442
R01 · FY2019 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$384,867
R01 · FY2019 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer$180,426
R21 · FY2019 · CA · contact PI
Program 12: Developmental Therapeutics$91,416
P30 · FY2019 · CA · contact PI
Program 12: Developmental Therapeutics$6,168
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,952,701
UM1 · FY2018 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2018 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$636,708
R01 · FY2018 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$396,771
R01 · FY2018 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer$207,757
R21 · FY2018 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$180,136
R01 · FY2018 · CA · contact PI
Immunotherapeutic Approaches Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$177,751
R21 · FY2018 · CA · contact PI
Program 12: Developmental Therapeutics$94,678
P30 · FY2018 · CA · contact PI
Program 12: Developmental Therapeutics$11,430
P30 · FY2018 · CA · contact PI
Program 12: Developmental Therapeutics$5,849
P30 · FY2018 · CA · contact PI
Program 12: Developmental Therapeutics$5,123
P30 · FY2018 · CA · contact PI
Program 12: Developmental Therapeutics$3,833
P30 · FY2018 · CA · contact PI
Program 12: Developmental Therapeutics$1,602
P30 · FY2018 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$642,150
R01 · FY2017 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Multiple Myeloma$306,345
P50 · FY2017 · CA · contact PI
Immunotherapeutic Approaches Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$199,501
R21 · FY2017 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$126,024
R01 · FY2017 · CA · contact PI
Program 12: Developmental Therapeutics$64,297
P30 · FY2017 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,765,337
UM1 · FY2016 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$713,143
UM1 · FY2016 · CA
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$534,201
R01 · FY2016 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$363,125
R01 · FY2016 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Multiple Myeloma$285,578
P50 · FY2016 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$116,603
R01 · FY2016 · CA · contact PI
Translational Pharmacology and Early Therapeutic Trials$93,190
P30 · FY2016 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,513,183
UM1 · FY2015 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$534,201
R01 · FY2015 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$363,125
R01 · FY2015 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Multiple Myeloma$288,616
P50 · FY2015 · CA · contact PI
Translational Pharmacology and Early Therapeutic Trials$93,224
P30 · FY2015 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$89,819
R01 · FY2015 · CA · contact PI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,400,003
UM1 · FY2014 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$518,175
R01 · FY2014 · CA · contact PI
Adoptive Immunotherapy for Multiple Myeloma Using Educated T Cells$422,305
P01 · FY2014 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$352,231
R01 · FY2014 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Multiple Myeloma$285,641
P50 · FY2014 · CA · contact PI
Translational Pharmacology and Early Therapeutic Trials$88,329
P30 · FY2014 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$634,271
U01 · FY2013 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$502,149
R01 · FY2013 · CA · contact PI
Adoptive Immunotherapy for Multiple Myeloma Using Educated T Cells$356,263
P01 · FY2013 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$341,338
R01 · FY2013 · CA · contact PI
Targeting the MUC1-C Oncoprotein in Multiple Myeloma$281,589
P50 · FY2013 · CA · contact PI
P5 - Adoptive Immunotherapy for Renal Carcinoma Usng Dendritic Cell/Tumor Fusions$246,790
P50 · FY2013 · CA · contact PI
Translational Pharmacology and Early Therapeutic Trials$85,483
P30 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$654,181
U01 · FY2012 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$534,201
R01 · FY2012 · CA · contact PI
Adoptive Immunotherapy for Multiple Myeloma Using Educated T Cells$437,181
P01 · FY2012 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$363,125
R01 · FY2012 · CA · contact PI
Differentiating Agents in Hematologic Malignancies$323,814
R01 · FY2012 · CA · contact PI
P5 - Adoptive Immunotherapy for Renal Carcinoma Usng Dendritic Cell/Tumor Fusions$263,451
P50 · FY2012 · CA · contact PI
Translational Pharmacology and Early Therapeutic Trials$93,207
P30 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$590,517
U01 · FY2011 · CA · contact PI
Adoptive Immunotherapy for Multiple Myeloma Using Educated T Cells$437,562
P01 · FY2011 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$358,868
R01 · FY2011 · CA · contact PI
Differentiating Agents in Hematologic Malignancies$323,814
R01 · FY2011 · CA · contact PI
P5 - Adoptive Immunotherapy for Renal Carcinoma Usng Dendritic Cell/Tumor Fusions$248,686
P50 · FY2011 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$645,402
U01 · FY2010 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$369,968
R01 · FY2010 · CA · contact PI
Differentiating Agents in Hematologic Malignancies$333,828
R01 · FY2010 · CA · contact PI
Adoptive Immunotherapy for Multiple Myeloma Using Educated T Cells$324,064
P01 · FY2010 · CA · contact PI
P5 - Adoptive Immunotherapy for Renal Carcinoma Usng Dendritic Cell/Tumor Fusions$259,889
P50 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$798,964
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$748,484
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$657,112
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$632,747
U01 · FY2009 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$369,968
R01 · FY2009 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$343,705
R01 · FY2009 · CA · contact PI
Differentiating Agents in Hematologic Malignancies$333,828
R01 · FY2009 · CA · contact PI
Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/Tumor Fusions$257,649
P50 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$613,306
U01 · FY2008 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$369,968
R01 · FY2008 · CA · contact PI
Differentiating Agents in Hematologic Malignancies$333,828
R01 · FY2008 · CA · contact PI
Novel Immunotherapeutic Approaches for Ovarian Cancer$303,237
P50 · FY2008 · CA · contact PI
Phase I Trials of New Anti-Cancer Agents$602,616
U01 · FY2007 · CA · contact PI
Novel Immunotherapeutic Approaches for Ovarian Cancer$333,465
P50 · FY2007 · CA · contact PI
Regulation of Oxidative Stress Response by c-Abl and Arg$324,685
R01 · FY2007 · CA · contact PI
Phase I Trials of New Anti-Cancer Agents$568,485
U01 · FY2006 · CA · contact PI
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$371,534
R01 · FY2006 · CA · contact PI
Regulation of Oxidative Stress Response by c-Abl and Arg$334,381
R01 · FY2006 · CA · contact PI
Differentiating Agents in Hematologic Malignancies$317,265
R01 · FY2006 · CA · contact PI
Novel Immunotherapeutic Approaches for Ovarian Cancer$220,532
P50 · FY2006 · CA · contact PI
Phase I Trials of New Anti-Cancer Agents$480,518
U01 · FY2005 · CA
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$380,475
R01 · FY2005 · CA
Regulation of Oxidative Stress Response by c-Abl and Arg$342,428
R01 · FY2005 · CA
Differentiating Agents in Hematologic Malignancies$324,900
R01 · FY2005 · CA
Molecular Mechanisms of Ara-C Therapy in Man$283,860
R01 · FY2005 · CA
Novel Immunotherapeutic Approaches for Ovarian Cancer$221,068
P50 · FY2005 · CA
Phase I Trials of New Anti-Cancer Agents$569,524
U01 · FY2004 · CA
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$380,475
R01 · FY2004 · CA
Regulation of Oxidative Stress Response by c-Abl and Arg$342,428
R01 · FY2004 · CA
Differentiating Agents in Hematologic Malignancies$324,900
R01 · FY2004 · CA
Molecular Mechanisms of Ara-C Therapy in Man$283,860
R01 · FY2004 · CA
Novel Immunotherapeutic Approaches for Ovarian Cancer$219,136
P50 · FY2004 · CA
Phase I Trials of New Anti-Cancer Agents$663,502
U01 · FY2003 · CA
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$380,475
R01 · FY2003 · CA
Regulation of Oxidative Stress Response by c-Abl and Arg$342,428
R01 · FY2003 · CA
Differentiating Agents in Hematologic Malignancies$324,900
R01 · FY2003 · CA
Molecular Mechanisms of Ara-C Therapy in Man$283,860
R01 · FY2003 · CA
PHASE I TRIALS OF NEW ANTICANCER AGENTS$467,245
U01 · FY2002 · CA
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer$380,753
R01 · FY2002 · CA
Molecular Mechanisms of Ara-C Therapy in Man$283,930
R01 · FY2002 · CA
MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION$231,075
R01 · FY2002 · CA
Differentiating Agents in Hematologic Malignancies$189,761
R01 · FY2002 · CA
DEVELOPMENT OF MYELOMA VACCINES$109,507
P01 · FY2002 · CA
DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES$108,407
R01 · FY2002 · CA
PHASE I TRIALS OF NEW ANTICANCER AGENTS$455,760
U01 · FY2001 · CA
MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN$313,829
R01 · FY2001 · CA
Molecular Mechanisms of Ara-C Therapy in Man$284,759
R01 · FY2001 · CA
DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES$263,394
R01 · FY2001 · CA
MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION$231,750
R01 · FY2001 · CA
ONCOGENIC SIGNALING BY THE MUC1 BREAST CARCINOMA ANTIGEN$125,862
R21 · FY2001 · CA
DEVELOPMENT OF MYELOMA VACCINES$109,507
P01 · FY2001 · CA
PHOSPHORYLATION OF RAD51$0
P41 · FY2001 · RR
PHASE I TRIALS OF NEW ANTICANCER AGENTS$438,030
U01 · FY2000 · CA
MOLECULAR MECHANISMS OF ARA-C THERAPY IN MAN$306,068
R01 · FY2000 · CA
DEVELOPMENT OF MYELOMA VACCINES$275,287
P01 · FY2000 · CA
DIFFERENTIATING AGENTS IN HEMATOLOGIC MALIGNANCIES$257,087
R01 · FY2000 · CA
MOLECULAR REGULATION OF SIGNALING BY IONIZING RADIATION$232,200
R01 · FY2000 · CA
ONCOGENIC SIGNALING BY THE MUC1 BREAST CARCINOMA ANTIGEN$126,138
R21 · FY2000 · CA
PHOSPHORYLATION OF RAD51$8,199
P41 · FY2000 · RR
CORE--CANCER PHARMACOLOGY$0
P30 · FY2000 · CA